[2-(1-Hydroxy-2-oxo-2-phenylethyl)phenyl] acetate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: [2-(1-Hydroxy-2-oxo-2-phenylethyl)phenyl] acetate
• 英文别名: [2-(1-hydroxy-2-oxo-2-phenylethyl)phenyl] acetate
• 化学式: C₁₆H₁₄O₄
• 分子量: 270.28
• InChiKey: WZIYXARWTURBJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH ISOQUINOLINE AND QUINOLINE DERIVATIVES<br/>[FR] MÉTHODES ET COMPOSITIONS UTILES DANS LE TRAITEMENT DE MALADIES FAISANT APPEL À DES PROTÉINES DE LA FAMILLE BCL-2 ET DES DÉRIVÉS D'ISOQUINOLÉINE ET DE QUINOLÉINE
  申请人：RICHARD DAVID J

  公开号：WO2014081953A1

  公开（公告）日：2014-05-30

  The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

  本发明涉及用于癌症治疗的组合物和方法，例如造血系统癌症（如B细胞淋巴瘤）。在其他方面，该发明提供了治疗特定类型的造血系统癌症（如B细胞淋巴瘤）的方法，使用公开化合物中的一个或多个与例如26S蛋白酶抑制剂（例如Bortezomib）的组合。另一方面，本发明涉及使用公开化合物进行自身免疫治疗。另一方面，本发明涉及用于鉴定化合物的方法，例如BH3类模拟化合物，其具有预测体内有效性对抗B细胞淋巴瘤肿瘤和其他癌症以及自身免疫疾病的独特体外特性。
• [EN] INHIBITORS OF HUMAN 12/15-LIPOXYGENASE<br/>[FR] INHIBITEURS DE LA 12/15-LIPOXYGÉNASE- HUMAINE
  申请人：GEN HOSPITAL CORP

  公开号：WO2015027146A1

  公开（公告）日：2015-02-26

  A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.

  一项系统性筛选发现了一类化合物，具有对12/15-脂氧合酶的抑制作用。因此，本发明涉及使用这些化合物来抑制12/15-脂氧合酶并治疗涉及12/15-脂氧合酶的疾病。典型的疾病包括但不限于中风、脑室周围白质损伤、心脏骤停复苏、动脉硬化、帕金森病、阿尔茨海默病和乳腺癌。
• METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH ISOQUINOLINE AND QUINOLINE DERIVATIVES
  申请人：Eutropics Pharmaceuticals, Inc.

  公开号：EP2922544A1

  公开（公告）日：2015-09-30
• INHIBITORS OF HUMAN 12/15-LIPOXYGENASE
  申请人：The General Hospital Corporation

  公开号：EP3036226A1

  公开（公告）日：2016-06-29
• FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME
  申请人：Cydex Pharmaceuticals, Inc.

  公开号：EP3183295A1

  公开（公告）日：2017-06-28